The CuraVac MG therapeutic vaccine has the support of the European Commission in the form of a grant of € 6 million of a total budget of € 7.5 million.
Following a call for proposals that was answered by all the best medicine projects in the world, CuraVac’s project for a MG therapeutic vaccine was one of the 7 therapeutic vaccine projects that were selected by an Independent Jury Committee of the best world experts.
MYASTERIX is a 5-year European Collaborative Project supported by the European Commission under the Health Cooperation Work Program of the 7th Framework Program under the Grant Agreement nº 602420.
For official details from the European Commission, please follow the link to the official Community Research and Development Information Service.
Before the creation of CuraVac, the underlying fundamental research was supported by the National Institute of Health (NIH) and the Muscular Dystrophy Association (MDA).